Circulating HDL levels control hypothalamic astrogliosis via apoA-I

• Main Authors: Anna Götz, Maarit Lehti, Elizabeth Donelan, Cynthia Striese, Sebastian Cucuruz, Stephan Sachs, Chun-Xia Yi, Stephen C. Woods, Samuel D. Wright, Timo D. Müller, Matthias H. Tschöp, Yuanqing Gao, Susanna M. Hofmann
• Format: Article
• Language: English
• Published: Elsevier 2018-09-01
• Series: Journal of Lipid Research
• Subjects: mitochondria; inflammation; high density lipoprotein; apolipoprotein A-I; metabolism; dyslipidemia
• Online Access: http://www.sciencedirect.com/science/article/pii/S0022227520335343

Meta-inflammation of hypothalamic areas governing energy homeostasis has recently emerged as a process of potential pathophysiological relevance for the development of obesity and its metabolic sequelae. The current model suggests that diet-induced neuronal injury triggers microgliosis and astrocytosis, conditions which ultimately may induce functional impairment of hypothalamic circuits governing feeding behavior, systemic metabolism, and body weight. Epidemiological data indicate that low circulating HDL levels, besides conveying cardiovascular risk, also correlate strongly with obesity. We simulated that condition by using a genetic loss of function mouse model (apoA-I−/−) with markedly reduced HDL levels to investigate whether HDL may directly modulate hypothalamic inflammation. Astrogliosis was significantly enhanced in the hypothalami of apoA-I−/− compared with apoA-I+/+ mice and was associated with compromised mitochondrial function. apoA-I−/− mice exhibited key components of metabolic disease, like increased fat mass, fasting glucose levels, hepatic triglyceride content, and hepatic glucose output compared with apoA-I+/+ controls. Administration of reconstituted HDL (CSL-111) normalized hypothalamic inflammation and mitochondrial function markers in apoA-I−/− mice. Treatment of primary astrocytes with apoA-I resulted in enhanced mitochondrial activity, implying that circulating HDL levels are likely important for astrocyte function. HDL-based therapies may consequently avert reactive gliosis in hypothalamic astrocytes by improving mitochondrial bioenergetics and thereby offering potential treatment and prevention for obesity and metabolic disease.